Regulatory document
FDA to recommend additional, earlier MRI monitoring for patients with Alzheimer’s disease…
FDA Safety Communications · Information · USA · Aug 28, 2025
Key facts
| Title | FDA to recommend additional, earlier MRI monitoring for patients with Alzheimer’s disease taking Leqembi (lecanemab) |
|---|---|
| Issuer | FDA Safety Communications |
| Source | FDA Safety Communications |
| Document type | Information |
| Country or region | USA |
| Date | Aug 28, 2025 |
| Document | fda.gov |
| Issuer website | fda.gov |
At a glance
- Yes Full text searchable in Orca1
- 100–999 Documents from this issuer in Orca1
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Global regulations and guidance
Regulations, guidance and official notices from medical device and medicines regulators worldwide, collected by Orca1 from each issuer's website. Only the title, issuer, date and link are shown here; the full text is searchable in Orca1.
Source: Medical device and medicines regulators and agencies as named on each record (EMA, MHRA, TGA, CDSCO, PMDA, NMPA, Health Canada, HSA, the FDA and others), collected by Orca1 from each issuer's website · Source date: